aTYR PHARMA (ATYR) Assets Average (2015 - 2026)
aTYR PHARMA's (ATYR) quarterly Assets Average came in at $86.3 million in Q1 2026, down 11.04% YoY from $97.0 million in Q1 2025, and down 13.52% on a QoQ basis from $99.8 million in Q4 2025.
aTYR PHARMA (ATYR) Assets Average (2015 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 12 years of Assets Average data on file, last reported at $86.3 million in Q1 2026.
- Quarterly Assets Average fell 11.04% year-over-year to $86.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.3 million (down 11.04% YoY) and the FY2025 annual result came in at $94.9 million, down 12.71% from the prior year.
- Assets Average retreated to $86.3 million in Q1 2026, from $99.8 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $134.8 million in Q2 2023 to a low of $86.3 million in Q1 2026.
- A 5-year average of $106.6 million and a median of $100.4 million in 2022 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average soared 134.74% — and 2024, when it slipped 23.37%.
- Tracing ATYR's Assets Average over 5 years: stood at $95.9 million in 2022, then grew by 28.09% to $122.9 million in 2023, then fell by 23.31% to $94.2 million in 2024, then advanced by 5.95% to $99.8 million in 2025, then dropped by 13.52% to $86.3 million in 2026.
- The last three Assets Average figures came in at $86.3 million (Q1 2026), $99.8 million (Q4 2025), and $104.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | 74.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 74.74 Mn |
| Mar 31, 2026 | 86.33 Mn |
| Dec 31, 2025 | 99.83 Mn |
| Sep 30, 2025 | 104.09 Mn |
| Jun 30, 2025 | 99.39 Mn |
| Mar 31, 2025 | 97.04 Mn |
| Dec 31, 2024 | 94.22 Mn |
| Sep 30, 2024 | 98.78 Mn |
| Jun 30, 2024 | 109.60 Mn |
| Mar 31, 2024 | 116.95 Mn |
| Dec 31, 2023 | 122.86 Mn |
| Sep 30, 2023 | 128.91 Mn |
| Jun 30, 2023 | 134.79 Mn |
| Mar 31, 2023 | 116.31 Mn |
| Dec 31, 2022 | 95.92 Mn |
| Sep 30, 2022 | 96.04 Mn |
| Jun 30, 2022 | 100.40 Mn |
| Mar 31, 2022 | 110.16 Mn |
| Dec 31, 2021 | 119.73 Mn |
| Sep 30, 2021 | 86.46 Mn |